Supernus Pharmaceuticals | SUPN - Koszty Sprzedaży I Administracji





Koszty Sprzedaży I Administracji Zmiana Data
Abbott USD 3.13B 125M 2025-12
ANI Pharmaceuticals USD 82.79M 6.13M 2025-12
Aurora Cannabis CAD 40.62M 1.17M 2025-12
Bristol-Myers Squibb USD 2.18B 392M 2025-12
Canopy Growth CAD 28.9M 636K 2025-12
Cara Therapeutics USD 2.19M 2.45M 2025-09
Corcept Therapeutics USD 114.74M 7.77M 2025-12
Eisai JPY 111.72B 7.86B 2025-12
Eli Lilly USD 3.13B 391.3M 2025-12
Novo Nordisk DKK 17.44B 1.41B 2025-12
Pacira USD 91.87M 70K 2025-12
Perrigo USD 255.9M 10.2M 2025-12
Pfizer USD 4.08B 894M 2025-12
Supernus Pharmaceuticals USD 122.39M 57.29M 2025-12
United Therapeutics USD 190.6M 38.6M 2025-12
Xeris Pharmaceuticals USD 42.64M 3.82M 2025-12